A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-29. Anything still debated is marked as such rather than presented as settled.
在临床研究之外,特沙莫瑞林常被讨论为生长激素分泌促进剂,但这一说法需要限定。它并不等同于生长激素本身,也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力,另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中,尚未形成统一结论。
特沙莫瑞林是一种合成肽,其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰,这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂,可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物,而非小分子化合物。
监管记录显示,特沙莫瑞林于 2010 年在美国首次获得批准,用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验,而非体重或瘦体重的普遍改善。后续出现了不同制剂版本,但其核心适应症保持一致。关于长期心血管结局和死亡率影响,现有证据仍不充分。
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成肽 | 含 44 个氨基酸残基的 GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 用于抵抗二肽基肽酶 IV 降解 |
| 首次批准 | 2010 年,美国 | 用于 HIV 相关脂肪营养不良 |
| 作用靶点 | 生长激素释放激素受体 | 位于垂体前叶 |
| 主要研究终点 | 内脏脂肪变化 | 非总体重或瘦体重 |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
== Formulation == Aulus Cornelius Celsus details one version of the antidote in De Medicina (ca. AD 30). A recent translation is as follows: "But the most famous antidote is that of Mithridates, which that king is said to have taken daily and by it to have rendered his body safe against danger from poison". It contained:
== Further reading == Savulescu, Julian; Bostrom, Nick (2009). Human enhancement. Oxford: Oxford University Press. ISBN 978-0-19-929972-0. Savulescu, Julian; ter Meulen, Ruud; Kahane, Guy (2011). Enhancing human capacities. Chichester: Wiley-Blackwell. ISBN 978-1-4051-9581-2. Michael Bess (2015). Our Grandchildren Redesigned: Life in the Bioengineered Society of the Near Future. Beacon Press. ISBN 978-0-8070-5217-4. Bateman, Simone; Gayon, Jean; Allouche, Sylvie; Goffette, Jérôme; Marzano, Michela (2015). Inquiring into Human Enhancement: Interdisciplinary and International Perspectives (1 ed.). London: Palgrave Macmillan. ISBN 978-1-137-53006-6. Edwards, Gary (2016). "Enhancement". Encyclopedia of Global Bioethics. Springer International Publishing. pp. 1121–1130. doi:10.1007/978-3-319-09483-0_172. ISBN 978-3-319-09483-0. Jotterand, Fabrice; Ienca, Marcello (2024). The Routledge Handbook of the Ethics of Human Enhancement. New York: Routledge. ISBN 978-0-367-61579-6.
Intermediate schools are referred to as "middle schools" in the PGCPS system, and operate as grades 6–8 middle schools. Grades 7–9 junior high school were phased out in the mid-1980s. Recent efforts have been made to convert most middle schools to the more popular grades 6–8 model. Issues in the past such as over-enrollment, lack of classroom space, and funding, had made it hard to convert all middle schools to a grades 6–8 configuration, but with increased funding and the addition of new middle schools, the transition is slowly being made, to be completed by the beginning of SY2024-2025. Most middle schools in Prince George's County operate with a "comprehensive" model, as their base. Most students are assigned to a middle school based on an "attendance area." Most magnet programs operate as a "School-Within-A-School" model, where the magnet serves as an alternative program, in addition to the main comprehensive program, and students from outside the regular attendance area of the middle school are enrolled and accepted into the magnet, either through "continuity" (automatic continuation from an elementary school magnet program to the middle school level equivalent) or more commonly, through a magnet lottery, where students apply for a magnet program and are granted acceptance through a random drawing. Almost all middle schools have a whole-school "Signature Program" that includes a specialized program of instruction which is the foundation of the school's comprehensive program.
== Prognosis == Episcleritis is a benign, self-limiting condition, meaning patients recover without any treatment. Most cases of episcleritis resolve within 7–10 days. The nodular type is more aggressive and takes longer to resolve. Although rare, some cases may progress to scleritis. However, in general, episcleritis does not cause complications in the eye. Smoking tobacco delays the response to treatment in patients with episcleritis.
The South American bushmaster (Lachesis muta muta) is the longest species of venomous snake in the Western Hemisphere and the longest pit viper in the world. It is native to parts of South America, especially the equatorial forests east of the Andes. They are active at dusk or after dark and they are very secretive and elusive. This species is large, fast and has a reputation for being particularly aggressive when cornered. Some reports suggest that this species produces a large amount of venom that is weak compared to some other vipers. Others, however, suggest that such conclusions may not be accurate. These animals are badly affected by stress and rarely live long in captivity. This makes it difficult to obtain venom in useful quantities and good condition for study purposes. For example, Bolaños (1972) observed that venom yield from his specimens fell from 233 mg to 64 mg while they remained in his care. As the stress of being milked regularly has this effect on venom yield, it is reasoned that it may also affect venom toxicity. This may explain the disparity described by Hardy and Haad (1998) between the low laboratory toxicity of the venom and the high mortality rate of bite victims. However, wild specimens have an average venom yield per bite of 280–450 mg (dry weight) (U.S. Dept. Navy, 1968). According to (Sanchez et al., 1992), who used wild specimens from Pará, Brazil, the average venom yield per bite was 324 mg, with a range of 168–552 mg (dry weight). Brown (1973) gives the following LD50 values for mice: 1.5 mg/kg IV, 1.6–6.2 mg/kg IP, 6.0 mg/kg SC.
Sources: en.wikipedia.org
From the east, the East River Tunnels' lines 1 and 2 (the more southerly tubes) can only access tracks 5–17 and are used by most Amtrak and NJ Transit trains, while the East River Tunnels' lines 3 and 4 (the more northerly tubes) can only access tracks 14–21 and are mostly used by LIRR. From the west, the North River Tunnels can access tracks 1–19, while the Empire Connection can only access tracks 1–9 and the LIRR's West Side Yard can only access tracks 10–21. All station tracks are powered by 12 kV overhead wire. Tracks 5–21 also have 750 V DC third rail. Due to the lack of proper ventilation in the tunnels and station, only electric locomotives and dual-mode locomotives are scheduled to enter Penn Station. Diesel-only NJT trains terminate at Hoboken Terminal or Newark Penn Station, and diesel-only LIRR trains terminate at or prior to Long Island City. The established throughput capacity of the tunnels is 24–25 trains per hour in each direction for the North River Tunnels and 20–21 trains per hour in the peak direction for the East River Tunnels. Trains on track 18 open their doors only on the north side (platform 10).
== Education == In 1993, Townsend graduated from George Mason University with a Bachelor of Science in Biology and Mathematics. She went on to earn a Master of Science in Molecular Genetics from the same university. She received a doctoral degree from the University of Virginia School of Medicine where she focused on cancer cell biology and metabolism. From 2001 to 2004, she served as a post-doctoral fellow in Pharmacology and Experimental Therapeutics at Fox Chase Cancer Center.
Carboxypeptidase A - cleaves C-terminal Phe, Tyr, Trp, or Leu Carboxypeptidase B - cleaves C-terminal Lys or Arg Aminopeptidase - cleaves any N-terminal amino acid Prolinase - cleaves N-terminal Pro from dipeptides Prolidase - cleaves C-terminal Pro from dipeptides
=== Surveys and reference === Books Beckert, Sven (2014). Empire of Cotton: A Global History. Knopf Doubleday. ISBN 978-0-385-35325-0. Davies, Stephen (2008). "Slavery, World". In Hamowy, Ronald (ed.). The Encyclopedia of Libertarianism. Thousand Oaks, CA: Sage; Cato Institute. pp. 464–469. doi:10.4135/9781412965811.n285. ISBN 978-1-4129-6580-4. LCCN 2008009151. OCLC 750831024. Davis, David Brion (1988) [1966]. The Problem of Slavery in Western Culture. Oxford: Oxford University Press. ISBN 978-0-19-505639-6. Davis, David Brion (1999). The Problem of Slavery in the Age of Revolution, 1770–1823. Oxford University Press. ISBN 978-0-19-988083-6. Drescher, Seymour (2009). Abolition: A History of Slavery and Antislavery. Cambridge University Press. p. 281. ISBN 978-1-139-48296-7. Eden, Jeff (2018). Slavery and Empire in Central Asia. Cambridge University Press. ISBN 978-1-108-63732-9. Gordon, Murray (1989). Slavery in the Arab World. Rowman & Littlefield. ISBN 978-0-941533-30-0. Greene, Jacqueline Dembar (2001). Slavery in Ancient Egypt and Mesopotamia. Turtleback Books. ISBN 978-0-613-34472-2. Heuman, Gad J. (2003). The Slavery Reader. Psychology Press. ISBN 978-0-415-21304-2. Hogendorn, Jan; Johnson, Marion (2003). The Shell Money of the Slave Trade. Cambridge University Press. ISBN 978-0-521-54110-7. Lal, K.S. (1994). Muslim Slave System in Medieval India. Aditya Prakashan. ISBN 978-81-85689-67-8. Archived from the original on May 12, 2008. Miers, Suzanne; Kopytoff, Igor (1979). Slavery in Africa: Historical and Anthropological Perspectives.
Sources: en.wikipedia.org
NFEPP (N-(3-fluoro-1-phenethylpiperidin-4-yl)-N-phenylpropionamide) is an analgesic opioid chemical, similar in structure to fentanyl, designed in 2016 by Spahn et al. from Free University of Berlin to avoid the standard negative side effects of opiates, including opioid overdose, by only targeting inflamed tissue.
Bevan later appears on television defending the government while acknowledging her own role in supporting Tender. After Henry is arrested and agrees to testify, he contacts Bevan about possible Russian intelligence involvement in Tender’s operations; she attempts to escalate the matter to the prime minister but is warned by the chief of staff against pursuing it further, due to the potential diplomatic ramifications and the credibility of Bevan's sources.
=== Beer–Lambert law === The roots of the term absorbance are in the Beer–Lambert law (or Beer's law). As light moves through a medium, it will become dimmer as it is being "extinguished". Pierre Bouguer recognized that this extinction (now often called attenuation) was not linear with distance traveled through the medium, but related to what is now referred to as an exponential function. If
allele One of multiple alternative versions of an individual gene, each of which is a viable DNA sequence occupying a given position, or locus, on a chromosome. For example, in humans, one allele of the eye-color gene produces blue eyes and another allele of the same gene produces brown eyes.
In humans, dominant negative mutations have been implicated in cancer (e.g., mutations in genes p53, ATM, CEBPA, and PPARgamma). Marfan syndrome is caused by mutations in the FBN1 gene, located on chromosome 15, which encodes fibrillin-1, a glycoprotein component of the extracellular matrix. Marfan syndrome is also an example of dominant negative mutation and haploinsufficiency. Lethal mutations result in rapid organismal death when occurring during development and cause significant reductions of life expectancy for developed organisms. An example of a disease that is caused by a dominant lethal mutation is Huntington's disease. Null mutations, also known as amorphic mutations, are a form of loss-of-function mutations that completely prohibit the gene's function. The mutation leads to a complete loss of operation at the phenotypic level, also causing no gene product to be formed. Atopic eczema and dermatitis syndrome are common diseases caused by a null mutation of the gene that activates filaggrin. Suppressor mutations are a type of mutation that causes the double mutation to appear normally. In suppressor mutations the phenotypic activity of a different mutation is completely suppressed, thus causing the double mutation to look normal. There are two types of suppressor mutations: intragenic and extragenic. Intragenic mutations occur in the gene where the first mutation occurs, while extragenic mutations occur in the gene that interacts with the product of the first mutation. A common disease that results from this type of mutation is Alzheimer's disease.
Sources: en.wikipedia.org
特沙莫瑞林是国际非专利名称,指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽,序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。
监管批准集中于 HIV 感染相关的脂肪营养不良,目的是减少内脏脂肪。它未被批准用于普通肥胖或一般体重管理。不同国家的批准状态和标签范围可能不同。
长期心血管获益、死亡率影响以及停药后的持续性仍缺乏确证。部分研究提示 IGF-1 和血糖参数可能变化,但个体差异较大。这些开放问题需要更长期、更大规模的试验来回答。
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.